EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors

Anke C Fender, Dobromir Dobrev

Naunyn-Schmiedeberg's Archives of Pharmacology · 2023-04 · 396 (4) · 589-592

DOI: 10.1007/s00210-023-02459-9 ↗

Kurz gefasst

Editorial in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 21.03.2023. Verfasst von Anke C Fender und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Universitätsklinikum Essen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The youngest type of antidiabetic agents, the so-called gliflozins or flozins, appear to have multifaceted pleiotropic effects. Canagliflozin was the first of the selective sodiumglucose cotransporter type 2 inhibitors (SGLT2i) to be approved, followed by empagliflozin, dapagliflozin, and others, to lower blood glucose in patients with type 2 diabetes (T2D). Unexpectedly, they also reduce cardiovascular mortality and the need for hospitalization in patients with heart failure (HF), regardless of the presence or absence of T2D. Accordingly, in 2022, the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines revised the treatment guidelines for the management of HF (Heidenreich et al. 2022) by including SGLT2i in their recommendations. Among the top ten takehome messages of the amended guidelines was the Class 2a recommendation for SGLT2i for therapy of HF with both preserved or mildly reduced ejection fraction (HFpEF, HFmrEF). Traditional approaches, including the beta-blockers and inhibitors of the renin–angiotensin–aldosterone system, obtained only a Class 2b recommendation. The cardioprotection afforded by SGLT2i is notably independent of the glucose-lowering effect, and this, together with the largely absent expression of SGLT2 in most cell types present in the heart, presents a clear case of pleiotropic, off-target actions that are incompletely understood (Chen et al. 2022; Packer 2022). Insights into the mechanistic basis of SGLT2i actions were recently gained by applying deep learning AI to artificial neural networks (BayesGenis et al. 2021). The SGLT2i were predicted to reduce oxidative stress in cardiomyocytes and to decrease stiffness, extracellular matrix remodeling, concentric hypertrophy, and systemic inflammation most likely through inhibition of the Na+/H+ exchanger 1 (NHE-1). Intracellular Na+ accumulation is a key feature of failing cardiomyocytes, linked with derailed homeostasis and loss of contractility. Experimental and clinical evidence suggests that SGLT2i lower intracellular Na+ in cardiomyocytes, again independently of effects on glucose homeostasis (Baartscheer et al. 2017; Karg et al. 2018; Uthman et al. 2018). Molecular docking studies have confirmed the ability of the SGLT2i dapagliflozin to bind both NHE-1 and the Na+-Ca2+ exchanger (Yu et al. 2021). Elegant studies in cell-based and in vivo mouse models of ischemia and reperfusion (I/R) revealed that dapagliflozin could alleviate inflammatory stress by reducing Na+ and Ca2+ overload, protect lysosome integrity and function, and promote autophagosome degradation (Yu et al. 2021). Augmented autophagic flux appears to constitute the main mechanism by which SGLT2i improve cardiomyocyte homeostasis and metabolic flexibility (Madonna et al. 2023; Packer 2020, 2022; Wang et al. 2022, 2020; Yu et al. 2021). Finally, SGLT2i may also cause a shift in the transcriptional landscape of cardiomyocytes that mimics nutrient and oxygen deprivation, leading to activation of the autophagyregulating platforms adenosine monophosphate-activated protein kinase (AMPK), the sirtuins SIRT1 and SIRT3, and hypoxia-inducible factors (HIF)-1α/2α, among others. One important target for autophagosome phagocytosis and clearance in response to SGLT2i is the intracellular alarmin sensor NLRP3 (NLR family pyrin domain containing 3). The NLRP3-containing inflammasome is a multiprotein platform for the auto-activation of caspase-1, leading to the maturation of pro-interleukins (IL)-1β and IL-18. Caspase-1 also cleaves gasdermin D, a prerequisite for the formation of a pyroptotic pore through which IL1-β and IL-18 are secreted and propagate the inflammatory signal. Dapagliflozin applied prior to I/R in mice improved autophagic flux and reduced the activation of the NLRP3 system. Accordingly, cardiac caspase-1 activity and serum IL-1β levels were reduced, which was associated with a decrease in infarct size and serum marker enzymes (Yu et al. 2021). Numerous other * Dobromir Dobrev dobromir.dobrev@uk-essen.de

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansHypoglycemic Agents

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
  • Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. dobromir.dobrev@uk-essen.de.

Förderung

  • NHLBI NIH HHS
  • Universitätsklinikum Essen

Zitieren

APA

Fender, A. C., & Dobrev, D. (2023). Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology, 396(4), 589-592. https://doi.org/10.1007/s00210-023-02459-9

Vancouver

Fender AC, Dobrev D. Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023;396(4):589-592. doi:10.1007/s00210-023-02459-9

BibTeX
@article{Fender2023,
  author = {Fender, Anke C and Dobrev, Dobromir},
  title = {Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2023},
  volume = {396},
  number = {4},
  pages = {589--592},
  doi = {10.1007/s00210-023-02459-9}
}
Kostenlos starten →